WO1996006620A2
(en)
*
|
1994-08-29 |
1996-03-07 |
Wake Forest University |
Lipid analogs for treating viral infections
|
US7135584B2
(en)
*
|
1995-08-07 |
2006-11-14 |
Wake Forest University |
Lipid analogs for treating viral infections
|
UA72558C2
(uk)
*
|
1999-11-01 |
2005-03-15 |
Мерц Фарма Гмбх Унд Ко. Кгаа |
1-аміноалкілциклогексанові антагоністи рецептора nmda
|
US6444702B1
(en)
|
2000-02-22 |
2002-09-03 |
Neuromolecular, Inc. |
Aminoadamantane derivatives as therapeutic agents
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
JP5230052B2
(ja)
|
2000-05-26 |
2013-07-10 |
イデニクス(ケイマン)リミテツド |
フラビウイルスおよびペスチウイルス治療のための方法および組成物
|
TW593223B
(en)
*
|
2000-06-20 |
2004-06-21 |
Merz Pharma Gmbh & Co Kgaa |
1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
|
US6602862B1
(en)
*
|
2000-09-19 |
2003-08-05 |
Merz Pharma Gmbh & Co., Kgaa |
1-Amino-alkylcyclohexanes as trypanocidal agents
|
EP1411954B1
(en)
|
2000-10-18 |
2010-12-15 |
Pharmasset, Inc. |
Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
|
AU2002227252A1
(en)
*
|
2000-12-01 |
2002-06-11 |
Cornell Research Foundation |
Animal model for flaviviridae infection
|
US20040266723A1
(en)
*
|
2000-12-15 |
2004-12-30 |
Otto Michael J. |
Antiviral agents for treatment of Flaviviridae infections
|
JP2005506292A
(ja)
*
|
2001-03-08 |
2005-03-03 |
エモリー ユニバーシティ |
pHに依存するNMDAレセプターアンタゴニスト
|
EP1435974A4
(en)
*
|
2001-09-28 |
2006-09-06 |
Idenix Cayman Ltd |
METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS WITH 4'-MODIFIED NUCLEOSIDES
|
US6828462B2
(en)
*
|
2001-11-07 |
2004-12-07 |
Merz Pharma Gmbh & Co. Kgaa |
Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
|
KR20040094692A
(ko)
*
|
2002-02-14 |
2004-11-10 |
파마셋, 리미티드 |
변형된 불소화 뉴클레오사이드 유사체
|
TW200500374A
(en)
|
2002-06-28 |
2005-01-01 |
Idenlx Cayman Ltd |
2' and 3' -nucleoside produrgs for treating flavivridae infections
|
US20040019118A1
(en)
*
|
2002-07-19 |
2004-01-29 |
Khalid Iqbal |
NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
|
CA2494340C
(en)
*
|
2002-08-01 |
2012-01-24 |
Pharmasset Inc. |
Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
|
EP1556019A2
(en)
|
2002-10-24 |
2005-07-27 |
Merz Pharma GmbH & Co. KGaA |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
CA2506129C
(en)
|
2002-11-15 |
2015-02-17 |
Idenix (Cayman) Limited |
2'-branched nucleosides and flaviviridae mutation
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
WO2005000216A2
(en)
|
2003-05-27 |
2005-01-06 |
Forest Laboratories, Inc. |
Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
|
WO2005003147A2
(en)
|
2003-05-30 |
2005-01-13 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
WO2005009418A2
(en)
*
|
2003-07-25 |
2005-02-03 |
Idenix (Cayman) Limited |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
|
WO2005009421A2
(en)
*
|
2003-07-28 |
2005-02-03 |
Merz Pharma Gmbh & Co. Kgaa |
The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
|
US20050113458A1
(en)
*
|
2003-10-22 |
2005-05-26 |
Forest Laboratories, Inc. |
Use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic a-beta peptides in amyloidopathies
|
AR046314A1
(es)
|
2003-11-05 |
2005-11-30 |
Merz Pharma Gmbh & Co Kgaa |
Composiciones que comprenden ciclohexilaminas y aminoadamantanos
|
UY28650A1
(es)
*
|
2003-12-05 |
2005-02-28 |
Forest Laboratories |
Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
PL1703902T3
(pl)
*
|
2004-01-05 |
2011-04-29 |
Merz Pharma Gmbh & Co Kgaa |
Memantyna do leczenia choroby Alzheimera o łagodnym do umiarkowanego stopniu zaawansowania
|
US20050187191A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Louis S. |
Methods and compositions for the treatment of respiratory syncytial virus
|
US20050187192A1
(en)
*
|
2004-02-20 |
2005-08-25 |
Kucera Pharmaceutical Company |
Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
|
TW200531680A
(en)
*
|
2004-03-03 |
2005-10-01 |
Merz Pharma Gmbh & Co Kgaa |
Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
|
MXPA06014587A
(es)
*
|
2004-06-17 |
2007-04-27 |
Forest Laboratories |
Formulaciones de liberacion modificada de formulaciones de dosificacion oral de memantina.
|
CN101389315A
(zh)
*
|
2004-06-17 |
2009-03-18 |
莫茨药物股份两合公司 |
美金刚口服剂型即释制剂
|
US20060002999A1
(en)
*
|
2004-06-17 |
2006-01-05 |
Forest Laboratories, Inc. |
Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
|
AU2005256963A1
(en)
*
|
2004-06-23 |
2006-01-05 |
Centre National De La Recherche Scientifique |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
SI3109244T1
(sl)
*
|
2004-09-14 |
2019-06-28 |
Gilead Pharmasset Llc |
Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov
|
TW200621677A
(en)
*
|
2004-09-21 |
2006-07-01 |
Astellas Pharma Inc |
Cyclic amine derivative or salt thereof
|
US20060205822A1
(en)
*
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
EA013474B1
(ru)
*
|
2005-06-16 |
2010-04-30 |
Форест Лэборэтериз, Инк. |
Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
|
US20070099947A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Alkermes, Inc. |
Methods and compositions for the treatment of brain reward system disorders by combination therapy
|
US20070141148A1
(en)
*
|
2005-11-30 |
2007-06-21 |
Merz Pharma Gmbh & Co. Kgaa |
Neramexane MR matrix tablet
|
RU2448976C2
(ru)
|
2006-04-11 |
2012-04-27 |
Новартис Аг |
Ингибиторы hcv/вич и их применение
|
EP2040676A2
(en)
*
|
2006-07-06 |
2009-04-01 |
Forest Laboratories, Inc. |
Orally dissolving formulations of memantine
|
CA2657106C
(en)
|
2006-07-18 |
2011-09-20 |
Astellas Pharma Inc. |
Aminoindane derivative or salt thereof
|
ATE488520T1
(de)
|
2006-08-04 |
2010-12-15 |
Merz Pharma Gmbh & Co Kgaa |
Pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
|
WO2008055945A1
(en)
|
2006-11-09 |
2008-05-15 |
Probiodrug Ag |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
ATE554085T1
(de)
|
2006-11-30 |
2012-05-15 |
Probiodrug Ag |
Neue inhibitoren von glutaminylcyclase
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
ATE525068T1
(de)
|
2007-02-28 |
2011-10-15 |
Conatus Pharmaceuticals Inc |
Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
|
EP2117540A1
(en)
|
2007-03-01 |
2009-11-18 |
Probiodrug AG |
New use of glutaminyl cyclase inhibitors
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
JP5667440B2
(ja)
|
2007-04-18 |
2015-02-12 |
プロビオドルグ エージー |
グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
|
TW200916091A
(en)
*
|
2007-06-08 |
2009-04-16 |
Merz Pharma Gmbh & Amp Co Kgaa |
Neramexane for the treatment of nystagmus
|
CN103058957A
(zh)
|
2007-06-29 |
2013-04-24 |
埃莫里大学 |
用于神经保护的nmda受体拮抗剂
|
EP2018854A1
(en)
*
|
2007-07-27 |
2009-01-28 |
Merz Pharma GmbH & Co. KGaA |
Novel combinations of neramexane for the treatment of neurodegenerative disorders
|
EP2200598A1
(en)
|
2007-09-12 |
2010-06-30 |
Merz Pharma GmbH & Co. KGaA |
Interval therapy for the treatment of tinnitus
|
RU2452476C2
(ru)
*
|
2007-09-12 |
2012-06-10 |
Мерц Фарма Гмбх Унд Ко. Кгаа |
Производные 1-аминоалкилциклогексана для лечения и предупреждения потери слуха
|
EP2085398A1
(en)
|
2008-02-01 |
2009-08-05 |
Merz Pharma GmbH & Co. KGaA |
Pyrazolopyrimidines, a process for their preparation and their use as medicine
|
EP2090576A1
(en)
|
2008-02-01 |
2009-08-19 |
Merz Pharma GmbH & Co.KGaA |
6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
WO2009151498A2
(en)
*
|
2008-03-28 |
2009-12-17 |
Forest Laboratories Holdings Limited |
Memantine formulations
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
EP2111858A1
(en)
|
2008-04-25 |
2009-10-28 |
EPFL Ecole Polytechnique Fédérale de Lausanne |
Novel treatment for alzheimer's disease
|
US20090275597A1
(en)
*
|
2008-05-02 |
2009-11-05 |
Forest Laboratories Holdings Limited |
Methods of treating cns disorders
|
US8173621B2
(en)
*
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
TW201010691A
(en)
*
|
2008-06-12 |
2010-03-16 |
Merz Pharma Gmbh & Co Kgaa |
1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
|
TW201006463A
(en)
*
|
2008-06-26 |
2010-02-16 |
Merz Pharma Gmbh & Co Kgaa |
Pharmaceutical compositions comprising aminocyclohexane derivatives
|
EP2476690A1
(en)
|
2008-07-02 |
2012-07-18 |
IDENIX Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
AU2009328497A1
(en)
|
2008-12-19 |
2010-06-24 |
Merz Pharma Gmbh & Co. Kgaa |
1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
|
TWI432188B
(zh)
|
2008-12-19 |
2014-04-01 |
Merz Pharma Gmbh & Co Kgaa |
供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類
|
CL2009002207A1
(es)
|
2008-12-23 |
2011-02-18 |
Gilead Pharmasset Llc |
Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
|
SG172363A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
WO2010075517A2
(en)
|
2008-12-23 |
2010-07-01 |
Pharmasset, Inc. |
Nucleoside analogs
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
TW201040130A
(en)
*
|
2009-04-17 |
2010-11-16 |
Merz Pharma Gmbh & Co Kgaa |
Synthesis of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
JP5749261B2
(ja)
*
|
2009-06-29 |
2015-07-15 |
メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー |
3,3,5,5−テトラメチルシクロヘキサノンを調製する方法
|
EP2448911A1
(en)
|
2009-06-29 |
2012-05-09 |
Merz Pharma GmbH & Co. KGaA |
Method of preparing 1-chloroacetamido-1,3,3,5,5-pentamethylcyclohexane
|
ES2461599T3
(es)
|
2009-06-29 |
2014-05-20 |
Merz Pharma Gmbh & Co. Kgaa |
Método para preparar 1-hidroxi-1,3,3,5,5-pentametilciclohexano
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
TW201116532A
(en)
|
2009-08-05 |
2011-05-16 |
Merz Pharma Gmbh & Co Kgaa |
Metabotropic glutamate receptor modulators
|
SG178953A1
(en)
|
2009-09-11 |
2012-04-27 |
Probiodrug Ag |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase
|
WO2011035924A1
(en)
*
|
2009-09-28 |
2011-03-31 |
Merz Pharma Gmbh & Co. Kgaa |
Method of preparing neramexane or a salt thereof
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
MX2012006877A
(es)
|
2009-12-18 |
2012-08-31 |
Idenix Pharmaceuticals Inc |
Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
|
US9181233B2
(en)
|
2010-03-03 |
2015-11-10 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
AU2011226074B2
(en)
|
2010-03-10 |
2015-01-22 |
Vivoryon Therapeutics N.V. |
Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
|
AP3515A
(en)
|
2010-03-31 |
2016-01-11 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
US8563530B2
(en)
|
2010-03-31 |
2013-10-22 |
Gilead Pharmassel LLC |
Purine nucleoside phosphoramidate
|
WO2011123586A1
(en)
|
2010-04-01 |
2011-10-06 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
US20110294890A1
(en)
|
2010-05-28 |
2011-12-01 |
Merz Pharma Gmbh & Co. Kgaa |
Neramexane for the treatment or prevention of inner ear disorders
|
CN102858321A
(zh)
*
|
2010-06-18 |
2013-01-02 |
莫茨药物股份两合公司 |
用于局部使用1-氨基-烷基环己烷衍生物的凝胶制剂
|
EA201390532A1
(ru)
|
2010-10-08 |
2013-09-30 |
Новартис Аг |
Композиции сульфамидых ингибиторов ns3, содержащие витамин е
|
WO2012048871A1
(en)
|
2010-10-12 |
2012-04-19 |
Merz Pharma Gmbh & Co. Kgaa |
Memantine for improving cognitive performance in subjects
|
JP6069215B2
(ja)
|
2010-11-30 |
2017-02-01 |
ギリアド ファーマセット エルエルシー |
化合物
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
EP2665474A1
(en)
|
2011-01-20 |
2013-11-27 |
Merz Pharma GmbH & Co. KGaA |
Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
WO2012107584A1
(en)
|
2011-02-11 |
2012-08-16 |
Universite Pierre Et Marie Curie (Paris 6) |
Methods for predicting outcome of a hepatitis virus infection
|
ES2570167T3
(es)
|
2011-03-16 |
2016-05-17 |
Probiodrug Ag |
Derivados de benzimidazol como inhibidores de glutaminil ciclasa
|
EP2691409B1
(en)
|
2011-03-31 |
2018-02-21 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
CA2843495A1
(en)
|
2011-08-03 |
2013-02-07 |
Cytheris |
Hcv immunotherapy
|
US9403863B2
(en)
|
2011-09-12 |
2016-08-02 |
Idenix Pharmaceuticals Llc |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013039855A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
EP2768838A1
(en)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
CA3131037A1
(en)
|
2011-11-30 |
2013-06-06 |
Emory University |
Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
WO2013133927A1
(en)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
AU2013266393B2
(en)
|
2012-05-22 |
2017-09-28 |
Idenix Pharmaceuticals Llc |
D-amino acid compounds for liver disease
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
RU2488388C1
(ru)
*
|
2012-05-24 |
2013-07-27 |
Ооо "Валента Интеллект" |
Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
|
UA107653U
(uk)
|
2012-10-01 |
2016-06-24 |
Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" |
Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
|
US10513534B2
(en)
|
2012-10-08 |
2019-12-24 |
Idenix Pharmaceuticals Llc |
2′-chloro nucleoside analogs for HCV infection
|
EP2909223B1
(en)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Dinucleotide compounds for hcv infection
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
EP2938624A1
(en)
|
2012-11-14 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
D-alanine ester of sp-nucleoside analog
|
EP2935304A1
(en)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
WO2014137930A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Thiophosphate nucleosides for the treatment of hcv
|
EP2970358B1
(en)
|
2013-03-04 |
2021-06-30 |
Idenix Pharmaceuticals LLC |
3'-deoxy nucleosides for the treatment of hcv
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2015017713A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
ES2900570T3
(es)
|
2013-08-27 |
2022-03-17 |
Gilead Pharmasset Llc |
Formulación de combinación de dos compuestos antivirales
|
EP3046924A1
(en)
|
2013-09-20 |
2016-07-27 |
IDENIX Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
WO2015066370A1
(en)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
EP3083654A1
(en)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
4'-or nucleosides for the treatment of hcv
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
WO2015134561A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
EP3568388A4
(en)
|
2017-01-10 |
2020-10-14 |
Owen-Barry Pharmaceuticals Inc. |
ANTICONVULSIVE CONNECTIONS
|
ES2812698T3
(es)
|
2017-09-29 |
2021-03-18 |
Probiodrug Ag |
Inhibidores de glutaminil ciclasa
|
WO2023154014A1
(en)
|
2022-02-08 |
2023-08-17 |
Sahin Fikret |
Nmdar antagonists prevent ageing and aging-associated conditions and diseases through increasing 20s proteasome activity
|